Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary

Human Pathology

Volumn 44, Issue 6, 2013, Pages 1017-1023

  Choi, Chel Hun ^a   Sung, Chang Ohk ^b   Kim, Ha Jeong ^a   Lee, Yoo Young ^a   Song, Sang Yong ^a   Song, Taejong ^c   Kim, Junhwan ^d   Kim, Tae Joong ^a   Lee, Jeong Won ^a   Bae, Duk Soo ^a   Kim, Byoung Gie ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c CHA University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Annexin A4; Nuclear staining; Ovarian serous carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; LIPOCORTIN 4; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; OVARY ADENOCARCINOMA; PAPILLARY SEROUS ADENOCARCINOMA OF THE OVARY; PROPORTIONAL HAZARDS MODEL; PROTEIN LOCALIZATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA ISOLATION; STAINING; TREATMENT RESPONSE;

ADULT; AGED; ANNEXIN A4; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84878111057     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.08.024     Document Type: Article

References (26)

1. I.B. Runnebaum, and E. Stickeler Epidemiological and molecular aspects of ovarian cancer risk J Cancer Res Clin Oncol 127 2001 73 79
2. K. Kim, and S.Y. Ryu Major clinical research advances in gynecologic cancer 2009 J Gynaecol Oncol 20 2009 203 209
3. A. du Bois, H.J. Luck, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
4. International Collaborative Ovarian Neoplasm Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
5. 2+ signalling to membrane dynamics Nat Rev Mol Cell Biol 6 2005 449 461
6. H.C. Edwards, and M.J. Crumpton Ca(2+)-dependent phospholipid and arachidonic acid binding by the placental annexins VI and IV Eur J Biochem 198 1991 121 129
7. V. Gerke, and S.E. Moss Annexins: from structure to function Physiol Rev 82 2002 331 371
8. U. Rescher, and V. Gerke Annexins - unique membrane binding proteins with diverse functions J Cell Sci 117 2004 2631 2639
9. S. Liemann, and R. Huber Three-dimensional structure of annexins Cell Mol Life Sci 53 1997 516 521
10. J.H. Rand The annexinopathies: a new category of diseases Biochim Biophys Acta 1498 2000 169 173
11. M.J. Hayes, and S.E. Moss Annexins and disease Biochem Biophys Res Commun 322 2004 1166 1170
12. S. Mussunoor, and G.I. Murray The role of annexins in tumour development and progression J Pathol 216 2008 131 140
13. P. Alfonso, M. Canamero, F. Fernandez-Carbonie, A. Nunez, and J.I. Casal Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling J Proteome Res 7 2008 4247 4255
14. R. Duncan, B. Carpenter, L.C. Main, C. Telfer, and G.I. Murray Characterisation and protein expression profiling of annexins in colorectal cancer Br J Cancer 98 2008 426 433
15. U. Zimmermann, S. Balabanov, and J. Giebel Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination Cancer Lett 209 2004 111 118
16. B. Sitek, J. Luttges, and K. Marcus Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma Proteomics 5 2005 2665 2679
17. A. Kim, T. Enomoto, and S. Serada Enhanced expression of annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin Int J Cancer 125 2009 2316 2322
18. A. Morita, E. Miyagi, H. Yasumitsu, H. Kawasaki, H. Hirano, and F. Hirahara Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma Proteomics 6 2006 5880 5890
19. Y. Miao, B. Cai, L. Liu, Y. Yang, and X. Wan Annexin IV is differentially expressed in clear cell carcinoma of the ovary Int J Gynecol Cancer 19 2009 1545 1549
20. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
21. J.W. Lee, C.H. Choi, and J.J. Choi Altered MicroRNA expression in cervical carcinomas Clin Cancer Res 14 2008 2535 2542
22. C.J. Kim, J.W. Lee, and J.J. Choi High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma Eur J Cancer 47 2011 918 925
23. A. Draeger, S. Wray, and E.B. Babiychuk Domain architecture of the smooth-muscle plasma membrane: regulation by annexins Biochem J 387 2005 309 314
24. K. Monastyrskaya, E.B. Babiychuk, and A. Draeger The annexins: spatial and temporal coordination of signaling events during cellular stress Cell Mol Life Sci 66 2009 2623 2642
25. 2+-dependent manner Cell Mol Life Sci 67 2010 2271 2281
26. J.F. Kidd, M.F. Pilkington, and M.J. Schell Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore J Biol Chem 277 2002 6504 6510